Ignite Creation Date:
2025-12-24 @ 6:59 PM
Ignite Modification Date:
2026-02-13 @ 4:26 PM
Study NCT ID:
NCT00110357
Status:
COMPLETED
Last Update Posted:
2015-12-24
First Post:
2005-05-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Sponsor:
Eli Lilly and Company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CA225-085
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None